Dividend Stocks

The Dividend Daily

Dividend stocks - News, notes, updates, and analysis, delivered fresh daily

Bristol Myers Squibb Posts Higher Profit, Exceeds Wall Street Estimates (BMY)

On Thursday biopharmaceutical firm Bristol Myers Squibb Co. (BMY) said it earned an increased profit in the quarter despite a drop in revenue.

The New York, New York-based company reported a fourth quarter net income of $925 million, or 56 cents per share, up compared to the $852 million, or 50 cents per share, earned a year earlier.

Adjusted earnings per share was 47 cents for the quarter. This beat Wall Street estimates as analysts were expecting an EPS of 43 cents.

The company’s revenue decreased by -23.18% to $4.19 billion. However, this still beat the analyst view of $4.12 billion.

Analysts are expecting the pharmaceutical company to earn $1.83 per share in the fiscal 2013. BMY is giving an EPS guidance of $1.78 to $1.88.

Bristol Myers Squibb shares were up 77 cents, or +2.21%, during morning trading on Thursday. The stock is up +10.45% over the past year.

The Bottom Line
We have been recommending shares of Bristol Myers Squibb (BMY) since Aug.25, 2009, when the stock was trading at $22.58. The company has a 4.01% dividend yield, based on last night’s closing stock price of $34.90.

Bristol Myers Squibb Co. (BMY) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

5 Rules of Winning Dividend Investing

FREE Dividend Stock Newsletter

Get the Dividend.com email newsletter to receive:

  • A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
  • Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
  • Tons of great market analysis and recommendations

Your Email

Free Dividend Newsletter

Get free dividend tips, analysis and updates straight to your inbox

Comments on this Article COMMENTS ON THIS ARTICLE

Comments are closed.

About This Article ABOUT THIS ARTICLE

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Disclaimer: Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.